GRANULES - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.6
| Stock Code | GRANULES | Market Cap | 13,406 Cr. | Current Price | 552 ₹ | High / Low | 627 ₹ |
| Stock P/E | 35.0 | Book Value | 146 ₹ | Dividend Yield | 0.27 % | ROCE | 10.9 % |
| ROE | 9.14 % | Face Value | 1.00 ₹ | DMA 50 | 575 ₹ | DMA 200 | 544 ₹ |
| Chg in FII Hold | -0.54 % | Chg in DII Hold | -0.44 % | PAT Qtr | 112 Cr. | PAT Prev Qtr | 121 Cr. |
| RSI | 41.0 | MACD | -6.69 | Volume | 3,39,725 | Avg Vol 1Wk | 9,90,645 |
| Low price | 412 ₹ | High price | 627 ₹ | PEG Ratio | -4.07 | Debt to equity | 0.29 |
| 52w Index | 65.2 % | Qtr Profit Var | 23.8 % | EPS | 16.3 ₹ | Industry PE | 29.0 |
📈 Chart & Trend Analysis: GRANULES is trading at ₹552, below its 50 DMA (₹575) but slightly above the 200 DMA (₹544). This indicates short-term weakness but medium-term support. RSI at 41.0 suggests the stock is approaching oversold territory, while MACD at -6.69 confirms bearish momentum. Bollinger Bands show price near the lower band, reflecting selling pressure and possible consolidation.
📊 Volume Trends: Current volume (3.39 lakh) is significantly lower than the 1-week average (9.90 lakh), suggesting weak participation and lack of momentum for a breakout.
🎯 Entry Zone: ₹540 – ₹555 (support near 200 DMA)
🚪 Exit Zone: ₹580 – ₹600 (resistance near 50 DMA and upper consolidation zone)
🔎 Trend Status: Consolidating with bearish bias — price is struggling below the 50 DMA, with weak RSI and negative MACD confirming downside pressure. A bounce from oversold levels could trigger short-term recovery, but trend remains weak.
Positive ✅
- EPS of ₹16.3 supports valuation strength.
- Quarterly PAT growth (₹112 Cr vs ₹121 Cr) shows resilience despite slight decline.
- 52-week performance index gain of 65.2% highlights long-term strength.
- Debt-to-equity ratio of 0.29 indicates manageable leverage.
Limitation ⚠️
- Price trading below 50 DMA indicates short-term weakness.
- ROE (9.14%) and ROCE (10.9%) are modest compared to sector leaders.
- PEG ratio of -4.07 highlights weak growth-adjusted valuation.
- Dividend yield of 0.27% is relatively low.
- Weak trading volume reduces breakout potential.
Company Negative News 📉
- Decline in FII holdings (-0.54%) and DII holdings (-0.44%) indicates reduced institutional confidence.
Company Positive News 📈
- Quarterly profit variation of 23.8% shows strong year-on-year growth.
- EPS of ₹16.3 reflects consistent earnings performance.
Industry 🌐
- Industry P/E at 29.0 suggests sector trades at premium valuations.
- Pharmaceutical sector benefits from global demand and regulatory approvals.
Conclusion 📝
GRANULES is consolidating with bearish bias, trading below its 50 DMA but supported by the 200 DMA. RSI near oversold and negative MACD confirm weakness, while low volume participation limits breakout potential. Entry near ₹540–₹555 offers margin of safety, while exits around ₹580–₹600 provide profit-taking opportunities. Fundamentally stable with manageable debt and long-term strength, but modest ROE/ROCE and weak PEG ratio suggest cautious optimism. Traders may play the consolidation range, while long-term investors should accumulate selectively given sector resilience.
Would you like me to extend this into a peer benchmarking overlay (comparing GRANULES against pharma peers like Divi’s Lab, Biocon, and Sun Pharma) so you can evaluate relative strength and sector rotation opportunities?